JO3039B1 - طريقة ومركب لعلاج فرط ضغط العين والجلوكوما - Google Patents

طريقة ومركب لعلاج فرط ضغط العين والجلوكوما

Info

Publication number
JO3039B1
JO3039B1 JOP/2009/0192A JOP20090192A JO3039B1 JO 3039 B1 JO3039 B1 JO 3039B1 JO P20090192 A JOP20090192 A JO P20090192A JO 3039 B1 JO3039 B1 JO 3039B1
Authority
JO
Jordan
Prior art keywords
glaucoma
ocular hypertension
composition
treating ocular
aqueous composition
Prior art date
Application number
JOP/2009/0192A
Other languages
English (en)
Inventor
Olli Oksala
Pertti Pellinen
Timo Reunamaki
Kari Lehmussaari
Original Assignee
Asahi Glass Co Ltd
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39940592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3039(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Glass Co Ltd, Santen Pharmaceutical Co Ltd filed Critical Asahi Glass Co Ltd
Application granted granted Critical
Publication of JO3039B1 publication Critical patent/JO3039B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبة مائية خاصة بالعيون محتوية على نظائر PGF2a لعلاج ارتفاع ضغط الدم في العين والجلوكوما، وبطريقة لعلاج ارتفاع ضغط الدم في العين والجلوكوما عن طريق اعطاء التركيبة المذكروة الى مريض في حاجة الى هذا العلاج، وبطريقة لزيادة قابلية نظائر PGF2a للذوبان في الماء وثباتها في تركيبة مائية
JOP/2009/0192A 2008-05-30 2009-05-27 طريقة ومركب لعلاج فرط ضغط العين والجلوكوما JO3039B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08397513A EP2127638A1 (en) 2008-05-30 2008-05-30 Method and composition for treating ocular hypertension and glaucoma

Publications (1)

Publication Number Publication Date
JO3039B1 true JO3039B1 (ar) 2016-09-05

Family

ID=39940592

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2009/0192A JO3039B1 (ar) 2008-05-30 2009-05-27 طريقة ومركب لعلاج فرط ضغط العين والجلوكوما

Country Status (27)

Country Link
US (3) US9999593B2 (ar)
EP (7) EP2127638A1 (ar)
JP (8) JP2011521943A (ar)
KR (5) KR102246598B1 (ar)
CN (1) CN102083413B (ar)
AR (2) AR071937A1 (ar)
AU (1) AU2009252210C1 (ar)
BR (1) BRPI0913109B8 (ar)
CA (2) CA2724194C (ar)
CY (2) CY1115565T1 (ar)
DK (4) DK3714877T3 (ar)
EA (1) EA023661B1 (ar)
ES (5) ES2907982T3 (ar)
GE (1) GEP20156220B (ar)
HR (4) HRP20220361T1 (ar)
HU (3) HUE058079T2 (ar)
JO (1) JO3039B1 (ar)
LT (3) LT3205334T (ar)
MX (1) MX2010012987A (ar)
MY (1) MY159463A (ar)
PL (4) PL2772249T3 (ar)
PT (4) PT3714877T (ar)
SG (1) SG191628A1 (ar)
SI (4) SI2306977T1 (ar)
TW (1) TWI432202B (ar)
UA (1) UA102257C2 (ar)
WO (1) WO2009145356A1 (ar)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
JP5681472B2 (ja) * 2009-12-28 2015-03-11 ロート製薬株式会社 眼科用組成物
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US9061034B2 (en) * 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
DK2598118T3 (en) 2010-07-29 2018-12-10 Allergan Inc CONSERVATIVE-FREE BIMATOPROST AND TIMOLOL SOLUTIONS
US20130245124A1 (en) * 2010-07-29 2013-09-19 Allergan, Inc. Preservative free bimatoprost solutions
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
ES2616089T3 (es) 2010-09-21 2017-06-09 S & V Technologies Gmbh Composición cosmética
EP2452669A1 (en) * 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
CA2830896A1 (en) * 2011-04-12 2012-10-18 Yukihiko Mashima Aqueous ophthalmic composition
CN102716074B (zh) * 2012-06-28 2013-10-16 武汉武药科技有限公司 一种贝美前列素滴眼剂及其制备方法
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
CA2935957C (en) 2014-01-10 2023-01-03 Manistee Partners Llc Treatment of migraines using topical administration of prostaglandin f2alpha analogs
CN104766952B (zh) * 2015-04-21 2017-01-25 武汉凯迪工程技术研究总院有限公司 利用生物质气化炉滤渣制备锂离子电池负极材料的方法
PL3103439T3 (pl) 2015-06-09 2019-12-31 Medproject Pharma-Entwicklungs- Und Vertriebsgesellschaft Mbh Zdolny do tworzenia kropli oftalmiczny żel bimatoprostu
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
AU2016349833A1 (en) * 2015-11-06 2018-05-24 Accuitis Pharmaceuticals, Inc. Use of proteasome inhibitors to treat ocular disorders
EP3423076B1 (en) 2016-02-29 2024-04-17 Sun Pharmaceutical Industries Limited Topical cyclosporine-containing formulations and uses thereof
GR1009040B (el) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
KR101770324B1 (ko) * 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
JP2020059652A (ja) * 2016-12-26 2020-04-16 参天製薬株式会社 タフルプロストとクエン酸エステルとを含有するデポ剤
WO2018181294A1 (ja) * 2017-03-27 2018-10-04 興和株式会社 医薬製剤
US20180318319A1 (en) * 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
JP6931493B2 (ja) 2017-06-22 2021-09-08 ヨンスン ファイン ケミカル カンパニー，リミテッド 緑内障治療用点眼組成物
TWI833535B (zh) * 2017-12-21 2024-02-21 日商參天製藥股份有限公司 賽佩普斯特(Sepetaprost)及Rho激酶抑制劑之組合醫藥
US20210282965A1 (en) 2018-07-09 2021-09-16 Warszawskie Zaklady Farmaceutyczne Polfa Sa Opthalmic dispensing device
CN111632025A (zh) * 2020-03-04 2020-09-08 吉林大学第一医院 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法
RU2761625C2 (ru) * 2021-02-11 2021-12-13 Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") Фармацевтическая композиция тафлупроста
TW202400133A (zh) * 2022-03-25 2024-01-01 日商坪田實驗室股份有限公司 水性組成物
WO2023241652A1 (zh) * 2022-06-16 2023-12-21 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778815A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
EP0286903B2 (en) 1987-04-03 2000-03-29 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
DE4027320C2 (de) 1990-08-29 1993-09-30 Ursapharm Arzneimittel Gmbh Fluid-Abgabeeinrichtung für keimfreies Fluid
JPH0655640A (ja) 1992-08-04 1994-03-01 Aavan Internatl:Kk 洗面台カウンター及びその製造方法
JPH06107547A (ja) 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
JP2510066Y2 (ja) 1993-01-20 1996-09-11 東洋製罐株式会社 加熱殺菌可能な液体医薬容器
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
EP1057486A1 (en) * 1995-11-17 2000-12-06 Alcon Laboratories, Inc. Use of drug combination for treating Glaucoma
EP0930296B2 (en) 1996-09-17 2005-11-02 Asahi Glass Company Ltd. Fluorinated prostaglandin derivatives and medicines
EP0944530A1 (en) 1996-12-09 1999-09-29 Bausch & Lomb Incorporated Single-use flexible container
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
CA2274708A1 (en) * 1997-10-13 1999-04-22 R-Tech Ueno, Ltd. Remedial composition for intraocular hypertension or glaucoma
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
GB2337740B (en) 1998-05-26 2000-11-15 Spreckelsen Mcgeough Ltd Fluid packaging
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
CN1146423C (zh) * 1998-07-14 2004-04-21 阿尔康实验室公司 前列腺素产品
BR9913955A (pt) 1998-09-25 2001-06-12 Alcon Lab Inc Composição oftalmológica confortável e de liberação sustentada e método para terapia ocular
US6096783A (en) 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
EP1905757A1 (en) 1999-04-06 2008-04-02 Sepracor Inc. Derivatives of Venlafaxine and methods of preparing and using the same
CA2413088C (en) 2000-06-19 2009-10-20 Kenji Morishima Preservative
JP3876355B2 (ja) * 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
WO2002022131A1 (fr) 2000-09-13 2002-03-21 Santen Pharmaceutical Co., Ltd. Collyre
TW586946B (en) * 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
WO2004006826A1 (ja) 2002-07-16 2004-01-22 Senju Pharmaceutical Co., Ltd. 薬液容器及びその製造方法
KR20050057251A (ko) 2002-09-09 2005-06-16 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 투명한 점안액
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
DE602004024427D1 (de) * 2003-07-31 2010-01-14 Santen Pharmaceutical Co Ltd Prostaglandin enthaltendes produkt
US20050287325A1 (en) * 2004-06-25 2005-12-29 Pharmacia & Upjohn Company Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients
DE602004017477D1 (de) * 2004-11-09 2008-12-11 Novagali Pharma Sa Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
US7562796B2 (en) 2004-11-24 2009-07-21 Holopack International Corp. Dispensing container with flow control system
KR101305649B1 (ko) 2004-12-09 2013-09-09 산텐 세이야꾸 가부시키가이샤 분자 내에 불소 원자를 갖는 프로스타글란딘 함유 제품
ATE555792T1 (de) 2004-12-24 2012-05-15 Santen Pharmaceutical Co Ltd Prostaglandin f2 alpha derivat enthaltende produkte
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
PL1905453T3 (pl) 2005-07-13 2013-02-28 Santen Pharmaceutical Co Ltd Kompozycja konserwująca do zastosowania okulistycznego
ES2460967T3 (es) 2005-08-02 2014-05-16 Santen Pharmaceutical Co., Ltd. Método para la prevención de la degradación de una sustancia térmicamente inestable
JP5247453B2 (ja) 2005-10-10 2013-07-24 ノバガリ ファルマ エスア プロスタグランジン含有眼科用カチオン性水中油型エマルジョン
FI126233B (sv) 2006-02-23 2016-08-31 Oy Kwh Mirka Ab Oscillerande slipmaskin
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
KR100927617B1 (ko) 2007-11-26 2009-11-23 한국표준과학연구원 열분해 탄소 성분의 나노 크기를 가지는 바이오 센서의감지부를 제작하는 방법
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma

Also Published As

Publication number Publication date
PL2772249T3 (pl) 2017-10-31
ES2968837T3 (es) 2024-05-14
LT3205334T (lt) 2020-09-25
JP7265584B2 (ja) 2023-04-26
DK3714877T3 (da) 2022-02-14
PL2306977T3 (pl) 2015-01-30
DK3205334T3 (da) 2020-07-13
EP2772249B1 (en) 2017-05-03
HRP20220361T1 (hr) 2022-05-13
GEP20156220B (en) 2015-01-26
CY1115565T1 (el) 2017-01-04
AU2009252210A1 (en) 2009-12-03
AU2009252210B2 (en) 2014-10-16
CA2965185A1 (en) 2009-12-03
MX2010012987A (es) 2011-02-24
DK2772249T3 (en) 2017-07-17
KR102114401B1 (ko) 2020-05-25
BRPI0913109B8 (pt) 2021-05-25
KR101820816B1 (ko) 2018-01-22
ES2808050T3 (es) 2021-02-25
TW201000104A (en) 2010-01-01
AU2009252210C1 (en) 2016-04-14
CN102083413B (zh) 2013-11-06
JP2023085558A (ja) 2023-06-20
ES2627837T8 (es) 2018-02-26
JP2017178957A (ja) 2017-10-05
JP2021120412A (ja) 2021-08-19
JP6889789B2 (ja) 2021-06-18
US20110152264A1 (en) 2011-06-23
KR101988642B1 (ko) 2019-06-12
MY159463A (en) 2017-01-13
ES2495316T3 (es) 2014-09-17
TWI432202B (zh) 2014-04-01
EP4035656A1 (en) 2022-08-03
LT2772249T (lt) 2017-09-11
PT3205334T (pt) 2020-07-31
PT3714877T (pt) 2022-03-10
JP2016065095A (ja) 2016-04-28
DK2306977T3 (da) 2014-09-15
KR20190067272A (ko) 2019-06-14
PL3714877T3 (pl) 2022-05-16
WO2009145356A1 (en) 2009-12-03
ES2627837T3 (es) 2017-07-31
HUE058079T2 (hu) 2022-06-28
EP2306977B1 (en) 2014-08-13
JP6356868B2 (ja) 2018-07-11
EA201071413A1 (ru) 2011-06-30
EP4289446A2 (en) 2023-12-13
JP6148317B2 (ja) 2017-06-14
HUE033103T2 (en) 2017-11-28
JP2020073574A (ja) 2020-05-14
SI2772249T1 (sl) 2017-08-31
AR071937A1 (es) 2010-07-28
KR20110011707A (ko) 2011-02-08
CY1120351T1 (el) 2019-07-10
EP2127638A1 (en) 2009-12-02
SI3714877T1 (sl) 2022-05-31
EA023661B1 (ru) 2016-06-30
US20180289618A1 (en) 2018-10-11
US10864159B2 (en) 2020-12-15
AR120961A2 (es) 2022-04-06
HUE049923T2 (hu) 2020-11-30
KR101650006B1 (ko) 2016-08-22
EP2772249A1 (en) 2014-09-03
KR20180008905A (ko) 2018-01-24
LT3714877T (lt) 2022-04-11
PL3205334T3 (pl) 2020-11-02
CA2724194A1 (en) 2009-12-03
EP3205334B1 (en) 2020-04-29
PT2772249T (pt) 2017-08-08
US20210059931A1 (en) 2021-03-04
HRP20170769T1 (hr) 2017-08-11
KR102246598B1 (ko) 2021-04-30
BRPI0913109A2 (pt) 2017-06-20
EP3714877B1 (en) 2022-01-26
KR20160102319A (ko) 2016-08-29
EP3205334A1 (en) 2017-08-16
BRPI0913109B1 (pt) 2019-10-22
EP4289446A3 (en) 2024-01-10
CA2724194C (en) 2017-06-27
JP6649992B2 (ja) 2020-02-19
EP4035656B1 (en) 2023-11-22
JP2011521943A (ja) 2011-07-28
ES2907982T3 (es) 2022-04-27
SI2306977T1 (sl) 2014-12-31
SI3205334T1 (sl) 2020-10-30
PT2306977E (pt) 2014-09-22
HRP20200998T1 (hr) 2020-10-16
EP2306977A1 (en) 2011-04-13
KR20200057801A (ko) 2020-05-26
JP2018154656A (ja) 2018-10-04
US9999593B2 (en) 2018-06-19
SG191628A1 (en) 2013-07-31
JP2014133765A (ja) 2014-07-24
HRP20140979T1 (hr) 2014-11-21
CN102083413A (zh) 2011-06-01
UA102257C2 (uk) 2013-06-25
EP3714877A1 (en) 2020-09-30

Similar Documents

Publication Publication Date Title
JO3039B1 (ar) طريقة ومركب لعلاج فرط ضغط العين والجلوكوما
MY175318A (en) Androgen composition for treating an opthalmic condition
AU2012307812A8 (en) Ophthalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
NZ608202A (en) Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
MX2013010039A (es) Composicion oftalmica de alta concentracion de olopatadina.
MX358176B (es) El uso de intensificadores, posiblemente asociados con riboflavina, asi como composiciones oftalmicas correspondientes para reticulacion de la cornea, en el tratamiento de queratocono o de otras alteraciones ectasicas de la córnea.
MY171920A (en) Prevention and treatment of ocular conditions
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201200762A1 (ru) Применение простагландинов f2-альфа и аналогов для заживления повреждений роговицы и конъюнктивы
EA201790889A1 (ru) Офтальмологический раствор
UA113627C2 (xx) Кристалічна форма циклоспорину a, фармацевтична композиція та спосіб лікування
EA201190337A1 (ru) Способ лечения
DK2257275T3 (da) Ketorolactromethaminsammensætninger til behandling eller forebyggelse af øjensmerte
EA201490721A1 (ru) Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы
EA201290603A1 (ru) Способ лечения
EA201490845A1 (ru) Улучшенная сшивающая композиция, доставляемая способом ионтофореза, пригодная для лечения кератоконуса
MY160383A (en) Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
ECSP12012033A (es) Triple combinación para bajar la presión intraocular
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MY157434A (en) Method for improving bioavailability of latanoprost
WO2012024419A3 (en) Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
MX2012005447A (es) Combinacion farmacéutica de compuesto de prostaglandina y nsaid (medicamentos antiinflamantorios no esteroideos) para el tratamiento de glaucoma e hipertensión ocular.
MX2010008308A (es) Tratamiento para trastornos relacionados con los ojos.
GB201107576D0 (en) Novel compounds and methods for use in medicine
MX2011007522A (es) Metodos de tratamiento de la infeccion por el virus del dengue mediante vitamina d.